Literature DB >> 16043017

Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis.

H Fai Poon1, Kenneth Hensley, Visith Thongboonkerd, Michael L Merchant, Bert C Lynn, William M Pierce, Jon B Klein, Vittorio Calabrese, D Allan Butterfield.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron degenerative disease characterized by the loss of neuronal function in the motor cortex, brain stem, and spinal cord. Familial ALS cases, accounting for 10-15% of all ALS disease, are caused by a gain-of-function mutation in Cu,Zn-superoxide dismutase (SOD1). Two hypotheses have been proposed to explain the toxic gain of function of mutant SOD (mSOD). One is that mSOD can directly promote reactive oxygen species and reactive nitrogen species generation, whereas the other hypothesis suggests that mSODs are prone to aggregation due to instability or association with other proteins. However, the hypotheses of oxidative stress and protein aggregation are not mutually exclusive. G93A-SOD1 transgenic mice show significantly increased protein carbonyl levels in their spinal cord from 2 to 4 months and eventually develop ALS-like motor neuron disease and die within 5-6 months. Here, we used a parallel proteomics approach to investigate the effect of the G93A-SOD1 mutation on protein oxidation in the spinal cord of G93A-SOD1 transgenic mice. Four proteins in the spinal cord of G93A-SOD1 transgenic mice have higher specific carbonyl levels compared to those of non-transgenic mice. These proteins are SOD1, translationally controlled tumor protein (TCTP), ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), and, possibly, alphaB-crystallin. Because oxidative modification can lead to structural alteration and activity decline, our current study suggests that oxidative modification of UCH-L1, TCTP, SOD1, and possibly alphaB-crystallin may play an important role in the neurodegeneration of ALS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043017     DOI: 10.1016/j.freeradbiomed.2005.03.030

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  51 in total

Review 1.  Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis.

Authors:  Lee J Martin
Journal:  IDrugs       Date:  2010-08

2.  Good science shows the way. Highlight Commentary on "Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis".

Authors:  Alvaro G Estévez
Journal:  Free Radic Biol Med       Date:  2007-04-19       Impact factor: 7.376

Review 3.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

4.  Upregulation of the E3 ligase NEDD4-1 by oxidative stress degrades IGF-1 receptor protein in neurodegeneration.

Authors:  Young-Don Kwak; Bin Wang; Jing Jing Li; Ruishan Wang; Qiyue Deng; Shiyong Diao; Yaomin Chen; Raymond Xu; Eliezer Masliah; Huaxi Xu; Jung-Joon Sung; Francesca-Fang Liao
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

5.  Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis.

Authors:  Hibiki Kawamata; Seng Kah Ng; Natalia Diaz; Suzanne Burstein; Lydie Morel; Alexandra Osgood; Brittany Sider; Haruki Higashimori; Philip G Haydon; Giovanni Manfredi; Yongjie Yang
Journal:  J Neurosci       Date:  2014-02-05       Impact factor: 6.167

6.  Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease.

Authors:  Fabio Di Domenico; Gilda Pupo; Antonella Tramutola; Alessandra Giorgi; Maria Eugenia Schininà; Raffaella Coccia; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2014-03-25       Impact factor: 7.376

Review 7.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

8.  The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice.

Authors:  Lee J Martin; Barry Gertz; Yan Pan; Ann C Price; Jeffery D Molkentin; Qing Chang
Journal:  Exp Neurol       Date:  2009-03-09       Impact factor: 5.330

Review 9.  The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?

Authors:  Junghee Lee; Jung Hyun Boo; Hoon Ryu
Journal:  Adv Drug Deliv Rev       Date:  2009-08-27       Impact factor: 15.470

10.  Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis.

Authors:  Luis B Tovar-Y-Romo; Luz Diana Santa-Cruz; Ricardo Tapia
Journal:  Mol Neurodegener       Date:  2009-07-20       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.